High-Attenuation Mucus (HAM) on CT is Pathognomonic for ABPA
High-attenuation mucus (HAM) on chest CT is the pathognomonic finding for allergic bronchopulmonary aspergillosis (ABPA) and confirms the diagnosis even when other diagnostic criteria are not fully met 1.
What Makes HAM Pathognomonic
HAM appears as mucus plugs with increased attenuation (brightness) on CT imaging compared to normal mucus. This finding is:
- Diagnostic on its own: The 2024 ISHAM-ABPA Working Group guidelines explicitly state that HAM confirms ABPA/ABPM diagnosis even if all other criteria are not fulfilled 1
- Highly specific: Found in approximately 20% of ABPA patients, it is considered nearly pathognomonic and does not occur in other conditions 2, 3
- Clinically significant: HAM indicates more severe, immunologically active disease and predicts higher risk of recurrent relapses 2
Other Supportive CT Findings (Not Pathognomonic)
While these findings support ABPA diagnosis, they are not pathognomonic:
- Central bronchiectasis: Previously considered characteristic, but up to 40% of ABPA cases show peripheral bronchiectasis, making this less specific 1, 2
- Mucus plugging (without high attenuation): Common but not diagnostic alone
- Fleeting opacities: High specificity but not pathognomonic 1
- Finger-in-glove opacities: Suggestive but can occur in other conditions
- Bronchiectasis with mucus plugging: Consistent with ABPA but requires additional criteria
Clinical Application
When you see HAM on thin-section chest CT:
- The diagnosis of ABPA/ABPM is confirmed
- You can proceed with treatment even if serum total IgE is <500 IU/mL or other criteria are incomplete 1
- This finding warrants classification as ABPA-HAM, indicating severe disease requiring aggressive management 1
Important Caveat
Approximately one-third of ABPA patients may have normal HRCT initially (serologic ABPA or ABPA-S), so the absence of HAM does not exclude ABPA 2. The diagnosis then requires meeting the full ISHAM criteria including elevated fungus-specific IgE, total IgE ≥500 IU/mL, and at least two other components.